Therapy Areas: Oncology
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
20 August 2026 - Clinical stage biotechnology company Annexin Pharmaceuticals AB (FN STO:ANNX) said on Thursday that the World Health Organization (WHO) has selected vanexin as the proposed Internatio...
Pillar Biosciences, LC-SCRUM-Asia and LSI Medience collaborate for liquid biopsy screening in lung cancer
20 August 2026 - US-based biotechnology company Pillar Biosciences Inc announced on Wednesday a collaboration with LC-SCRUM-Asia, a lung cancer screening project, and LSI Medience Corporation, a Japan...
BioArctic and Mesenkia sign research collaboration for glioblastoma antibody project
19 August 2026 - Swedish biopharma company BioArctic AB (STO: BIOA-B), which develops treatments for neurodegenerative diseases, said on Wednesday it has entered a research collaboration with Mesenkia...
Tolerance Bio licenses clinical-stage IL-7 therapy from NeoImmuneTech
19 August 2026 - Tolerance Bio Inc, a biotechnology company focused on preserving, regenerating and modulating thymic function to address immune diseases and extend healthspan, announced on Wednesday ...
Merck and Moderna report positive Phase 3 melanoma trial results
19 August 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, and biotechnology company Moderna Inc (NASDAQ:MRNA) announced on Wednesday that the Ph...
Scancell announces UK authorisation for Phase 3 melanoma trial
19 August 2026 - Immuno-oncology company Scancell Holdings plc (AIM: SCLP) announced on Wednesday that it has received Clinical Trial Authorization from the UK Medicines and Healthcare Products Regula...